Alesta Therapeutics Secures €65M Series A to Accelerate Pipeline of Oral Drugs Targeting Rare Diseases

Alesta Therapeutics, a biotechnology company focused on developing oral small molecule therapies for rare and underserved diseases, has raised €65 million in a Series A financing round. The funding will support the company’s preclinical and early clinical pipeline, further develop its proprietary drug discovery platform, and expand its research and development operations across Europe and the United States.

The round was co-led by Forbion and M Ventures, with participation from Sofinnova Partners, Jeito Capital, and Novo Holdings. The strong investor syndicate reflects growing confidence in Alesta’s approach to targeting diseases that lack effective treatments, particularly within the rare disease space, where innovation is both urgently needed and highly valued.

Founded in 2021 and headquartered in Basel, Switzerland, Alesta Therapeutics is developing a pipeline of orally available small molecules designed to modulate disease pathways that are often untreatable with conventional approaches. The company’s lead programs are focused on metabolic and neuromuscular rare diseases, with its most advanced candidate expected to enter Phase 1 trials in early 2026.

“Our mission is to make transformative therapies accessible to patients suffering from rare conditions, many of whom currently have no treatment options,” said Dr. Elena Richter, CEO and co-founder of Alesta Therapeutics. “This funding round is a major milestone that enables us to push forward our most promising programs and build a world-class team dedicated to this mission.”

Alesta’s proprietary platform integrates structure-based drug design, AI-enhanced screening, and disease-specific biomarker profiling to rapidly identify and optimize small molecules with high precision and potency. The company’s early data has shown promise in targeting pathways that have been difficult to modulate using traditional biologics or gene therapies.

Unlike many rare disease treatments that rely on complex biologics or one-time genetic interventions, Alesta is betting on the versatility and accessibility of small molecules. Oral medications offer several advantages: they are easier to manufacture and distribute, can be administered daily without medical supervision, and are often more cost-effective—critical factors when scaling treatments for rare conditions.

“The industry has made huge strides in rare disease research, but many patients are still left behind due to high treatment costs, limited availability, or poor therapeutic targeting,” said Dr. Thomas Van Beek, Partner at Forbion. “Alesta’s oral small molecule strategy is elegant in its simplicity and powerful in its potential impact.”

The €65 million investment will also allow Alesta to expand its operations, with plans to open a new research facility in the Netherlands and hire additional talent in medicinal chemistry, translational science, and clinical development. The company is also exploring strategic collaborations with academic centers and patient advocacy groups to enhance disease understanding and improve trial design.

“Our approach is rooted in collaboration,” said Dr. Richter. “We’re not just building a biotech company—we’re building a platform for discovery that involves scientists, clinicians, and patient communities from day one.”

In addition to progressing its lead candidates toward the clinic, Alesta plans to use part of the funds to further validate its discovery platform across additional rare disease indications. The company is currently evaluating targets in lysosomal storage disorders, inherited neuropathies, and ultra-rare mitochondrial diseases.

The rare disease sector remains a high-growth area within biotech, driven by regulatory incentives, strong patient advocacy, and scientific advances in precision medicine. According to a recent report by Evaluate Pharma, the global rare disease drug market is expected to surpass $270 billion by 2028.

“Alesta is perfectly positioned to lead a new wave of innovation in this space,” said Sophie Delacourt, Partner at Jeito Capital. “By combining cutting-edge science with an efficient, patient-centered approach, the team is charting a path to bring life-changing therapies to those who need them most.”

With this Series A financing, Alesta Therapeutics enters its next chapter with significant momentum, a clear vision, and the backing of some of Europe’s leading life science investors.